CDNA - Company ID 0001217234
CareDx, Inc. trades as CDNA and has a market capitalization of $1.47 B, making it the #2368 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $379.81M, up 13.8% from the prior year and net income of -$21.35M. This page tracks CareDx, Inc. through 1,334 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years CareDx, Inc.'s revenue grew from $40.63M to $379.81M, a compound annual growth rate of 28.2%. Net profit margin expanded from -97.1% to -5.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-14 |
| Insider trade | 4 | 2026-05-06 |
| Insider sale notice | 144 | 2026-05-05 |
| Insider trade | 4 | 2026-05-04 |
| Quarterly report | 10-Q | 2026-04-28 |
| S-3ASR | - | 2026-04-28 |
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences:
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a _qui tam_ action filed against the Company.
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants.
_First Quarter Revenue Growth of 39% Driven by Strong Performance Across Testing Services and Patient and Digital Solutions_
_Transaction extends CareDx’s Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM_
The largest companies sharing CareDx, Inc.'s SEC industry classification (services-medical laboratories).
CareDx, Inc. (CDNA) has a market capitalization of $1.47 B as of 2026-07-11, ranking #2368 among US-listed companies.
CareDx, Inc. reported revenue of $379.81M for fiscal year 2025, an increase of 13.8% year over year.
In its latest fiscal year CareDx, Inc. reported a net loss of $21.35M.